Related references
Note: Only part of the references are listed.Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials
Driton Vela et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)
ESCMID COVID-19 living guidelines: drug treatment and clinical management
Michele Bartoletti et al.
CLINICAL MICROBIOLOGY AND INFECTION (2022)
Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial*
Jennifer Tom et al.
CRITICAL CARE MEDICINE (2022)
Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis
Phei Ching Lim et al.
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES (2022)
Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
Rania M. Sarhan et al.
JOURNAL OF INFECTION AND PUBLIC HEALTH (2022)
Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial
Princy N. Kumar et al.
OPEN FORUM INFECTIOUS DISEASES (2022)
Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study
Niklas Broman et al.
CLINICAL MICROBIOLOGY AND INFECTION (2022)
Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19 A systematic review and meta-analysis
Jing Zhang et al.
MEDICINE (2022)
Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
Su-Yeon Yu et al.
EMERGING MICROBES & INFECTIONS (2022)
Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients
Abraham Rutgers et al.
PLOS ONE (2022)
Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study
Matilde Sanchez-Conde et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)
Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial
Alaa Rahhal et al.
MEDICINE (2022)
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)
Ivan O. Rosas et al.
ECLINICALMEDICINE (2022)
Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19
Emily C. Somers et al.
CLINICAL INFECTIOUS DISEASES (2021)
Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study
Krzysztof Tomasiewicz et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)
Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
Hong Zhao et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies
Jishnu Malgie et al.
CLINICAL INFECTIOUS DISEASES (2021)
IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study
Jose Maria Galvan-Roman et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
Shruti Gupta et al.
JAMA INTERNAL MEDICINE (2021)
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial
Olivier Hermine et al.
JAMA INTERNAL MEDICINE (2021)
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia A Randomized Clinical Trial
Carlo Salvarani et al.
JAMA INTERNAL MEDICINE (2021)
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Carlos Salama et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
Ivan O. Rosas et al.
INTENSIVE CARE MEDICINE (2021)
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
Viviane C. Veiga et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials
Chia Siang Kow et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
I. O. Rosas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
Anthony C. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open- label, multicentre, randomised, controlled, phase 3 trial
Arvinder S. Soin et al.
LANCET RESPIRATORY MEDICINE (2021)
Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial
Dongsheng Wang et al.
FRONTIERS OF MEDICINE (2021)
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani et al.
LANCET (2021)
Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
Robert Flisiak et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis
Manu Shankar-Hari et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials
Vijairam Selvaraj et al.
LUNG (2021)
Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison
Dujana Mostafa Hamed et al.
JOURNAL OF INFECTION AND PUBLIC HEALTH (2021)
Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
Dorota Zarebska-Michaluk et al.
JOURNAL OF INFLAMMATION RESEARCH (2021)
High-Dose Dexamethasone Versus Tocilizumab in Moderate to Severe COVID-19 Pneumonia: A Randomized Controlled Trial
Naveen B. Naik et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2021)
Effective treatment of severe COVID-19 patients with tocilizumab
Xiaoling Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
COVID-19 cytokine storm: the interplay between inflammation and coagulation
Ricardo J. Jose et al.
LANCET RESPIRATORY MEDICINE (2020)
Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab
M. Cellina et al.
DIAGNOSTIC AND INTERVENTIONAL IMAGING (2020)
Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study
Sofia Ramiro et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
IL-6-based mortality risk model for hospitalized patients with COVID-19
Rocio Laguna-Goya et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Bingwen Liu et al.
JOURNAL OF AUTOIMMUNITY (2020)
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study
Andrew Ip et al.
PLOS ONE (2020)
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Francesco Perrone et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cytokine Storm
David C. Fajgenbaum et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tocilizumab for severe COVID-19 pneumonia Reply
Giovanni Guaraldi et al.
LANCET RHEUMATOLOGY (2020)
Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review
Ryota Sakai et al.
CLINICAL RHEUMATOLOGY (2017)
IL-6 in Inflammation, Immunity, and Disease
Toshio Tanaka et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)